Bring on the fights! 💥
Lobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSD Lobe Sciences
October 4, 2021
Lobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSD Lobe Sciences
Psychedelics might reduce internalized shame and complex trauma symptoms in those with a history of
Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than
MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration A new study found
TRYP THERAPEUTICS SUBMITS IND APPLICATION FOR PHASE 2A CLINICAL TRIAL IN EATING DISORDERS Can shrooms
Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data Mydecine Innovations Group (MYCO)
Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials
Goodness Growth Holdings™ Subsidiary Resurgent Biosciences Launches First IRB-Approved Research Study on Entheogens & Psychedelic
Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for
Allied Corp. Advances Psilocybin Product Psilonex™ RX and Initiates Manufacturing Process Allied Corp. (ALID) has
Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes Nova Mentis (NOVA) was studying
Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub
Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada’s First Multiple-Dose Psilocybin Clinical Trial
This West Philly Doctor Says Psychedelic-Assisted Therapy Could Change Your Life Psychedelic therapy clinics continue
Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in its Long-Acting Next Generation
TRYP THERAPEUTICS COMPLETES PSYCHOTHERAPY TRAINING FOR PHASE 2A STUDY AT THE UNIVERSITY OF FLORIDA The
Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor
Clinical Trial Application Submitted to Health Canada for Experiential, Psychedelic-Assisted Psychotherapy Training Before a therapist
Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin There’s tremendous anecdotal
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder To Include Additional Behavioral
Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption If
Nova Mentis Files Fragile X Orphan Drug Designation with European Medicines Agency Fragile x syndrome
Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of
Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and